GAMIDA CELL
Gamida Cell is dedicated to making a significant difference in the clinical practice of modern medicine by first creating, then tapping the regenerative power of therapeutic stem cells. Gamida Cell is a leader in the development of stem cell therapy technologies and products. The therapies are based on expanded populations of cord blood stem cells, for the treatment of illnesses with significant unmet clinical needs such as blood cancers, autoimmune and metabolic diseases as well as neutropenia.
GAMIDA CELL
Industry:
Biotechnology Health Care Medical Device Therapeutics
Founded:
1998-01-01
Address:
Jerusalem, Yerushalayim, Israel
Country:
Israel
Website Url:
http://www.gamida-cell.com
Total Employee:
101+
Status:
Active
Contact:
97226595616
Total Funding:
267.75 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Alcresta
Alcresta develops enzyme-based nutritional products for infants and adults with acute and chronic diseases.
Eyevensys
Eyevensys creates ophthalmic therapeutic bio factories to sustainably treat major eye diseases.
Moximed
Moximed improves the standard of care for patients with osteoarthritis and investigates therapies to treat affected joints.
Novian Health
Novian Health is a medical device company transforming healthcare through innovation such as Novilase laser ablation for breast tumors.
P-Cure
P-Cure is a biotech company has developed a patient centric proton therapy solution with clinical benefits and financial advantages.
Reapplix
Reapplix identifies blood-derived proteins that improve wound healing, isolates them, and reapplies them to patients with chronic wounds.
Shanghai Cell Therapy Group
Shanghai Cell Therapy Group is a provider of cellular diagnosis center combining cellular research and treatment services.
Sino Biological
Sino Biological is a specialist provider of protein, antibody and gene products.
Current Advisors List
Board_member
2016-01-01
Board_member
2018-09-01
Board_member
Board_member
Board_member
Board_member
Board_member
Current Employees Featured
Jaren Madden Vice President, Investor Relations and Corporate Communications @ Gamida Cell
Vice President, Investor Relations and Corporate Communications
Tracey Lodie Chief Scientific Officer (Boston) @ Gamida Cell
Chief Scientific Officer (Boston)
2019-06-01
Dorit Harati VP, Quality Assurance @ Gamida Cell
VP, Quality Assurance
Julian Adams Chief Executive Officer @ Gamida Cell
Chief Executive Officer
2018-01-01
Joshua Hamermesh Chief Business Officer @ Gamida Cell
Chief Business Officer
2018-01-01
Ronit Simantov Chief Medical Officer @ Gamida Cell
Chief Medical Officer
Nurit Benjamini Director @ Gamida Cell
Director
2019-01-01
Michel Perry Director @ Gamida Cell
Director
2017-06-01
Naftali Brikashvili Senior Vice President, Finance and Operations @ Gamida Cell
Senior Vice President, Finance and Operations
2018-01-01
Shai Lankry Chief Financial Officer @ Gamida Cell
Chief Financial Officer
Founder
Stock Details
Investors List
Highbridge Capital Management
Highbridge Capital Management investment in Post-IPO Debt - Gamida Cell
Israel Innovation Authority
Israel Innovation Authority investment in Grant - Gamida Cell
Israel Biotech Fund
Israel Biotech Fund investment in Series F - Gamida Cell
Novartis
Novartis investment in Series F - Gamida Cell
Clal Biotechnology Industries
Clal Biotechnology Industries investment in Series F - Gamida Cell
Shavit Capital
Shavit Capital investment in Series F - Gamida Cell
Israel Healthcare Ventures
Israel Healthcare Ventures investment in Series F - Gamida Cell
VMS Asset Management
VMS Asset Management investment in Series F - Gamida Cell
Israel Innovation Authority
Israel Innovation Authority investment in Grant - Gamida Cell
Clal Biotechnology Industries
Clal Biotechnology Industries investment in Series E - Gamida Cell
Official Site Inspections
http://www.gamida-cell.com Semrush global rank: 4.14 M Semrush visits lastest month: 2.89 K
- Host name: 251.183.232.35.bc.googleusercontent.com
- IP address: 35.232.183.251
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Gamida Cell"
Gamida Cell - Crunchbase Company Profile & Funding
Gamida Cell is a biopharmaceutical company developing advanced cell therapies for patients with blood cancers and hematologic diseases. Its product includes …See details»
Who We Are - Gamida Cell
Gamida Cell has been in operation for over 20 years, developing deep expertise in the science of expanding and enhancing cells. We have assembled a strong team of pioneers with respected track records in cell therapy research and …See details»
Company Overview - Gamida Cell
Provided by Gamida Cell Ltd (the “Company”). The information in this Presentation is current only as of its date and may have changed since that date. These projections and forwardlooking …See details»
RoslinCT and Ayrmid Pharma Ltd. Announce Their Intent to Enter …
Mar 11, 2025 About Gamida Cell Gamida Cell Inc, a subsidiary of Ayrmid Pharma Ltd. ... RoslinCT is a leading global contract development and manufacturing services organization …See details»
Gamida Cell Announces Commencement of …
Mar 27, 2024 The newly reorganized Gamida Cell will issue contingent value rights with a potential aggregate maximum value of $27.5 million to holders of Gamida Cell’s ordinary shares, subject to the ...See details»
GAMIDA CELL INC. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for GAMIDA CELL INC. of Naples, FL. Get the latest business insights from Dun & Bradstreet.See details»
Gamida Cell Ltd. Overview | SignalHire Company Profile
Gamida Cell Ltd. is a public company that has been in the industry for 26 years. The company currently specializes in the Biotechnology, Biotechnology areas. The position of the Chairman …See details»
Gamida Cell - Funding, Financials, Valuation & Investors
Gamida Cell is registered under the ticker NASDAQ:GMDA . Their stock opened with $8.00 in its Oct 25, 2018 IPO. Gamida Cell is funded by 14 investors. Highbridge Capital Management …See details»
Gamida Cell 2025 Company Profile: Valuation, Funding ... - PitchBook
Gamida Cell Ltd is a clinical-stage biopharmaceutical company that is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid …See details»
Gamida Cell Ltd Company Profile - Overview - GlobalData
Gamida Cell Ltd (Gamida) is a healthcare company that develops allogeneic cell therapy products and candidates. Its proprietary nicotinamide (NAM) technology enhances and expands cells, …See details»
Organization | Gamida Cell
Organization Overview. First Clinical Trial. 2007 NCT00444262. First Marketed Drug. 2023 omidubicel . First NDA Approval. 2023 omidubicel ... GAMIDA | Gamida Cell ltd | Gamida Cell …See details»
Gamida Cell - Contacts, Employees, Board Members, Advisors
Organization. Gamida Cell . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 13. Number of Board …See details»
Gamida Cell Assist® - Cell Therapy Journey Support
If you are a healthcare provider and would like to find out where to treat your patients with Gamida Cell therapy, you can contact Gamida Cell Assist at 844-477-7478 or …See details»
Gamida Cell - Craft
Gamida Cell develops stem cell therapy technologies and products for the treatment of blood cancers, autoimmune and metabolic diseases. The Company’s scientists have developed a …See details»
RoslinCT and Ayrmid Pharma Ltd. Announce Their Intent to Enter …
BOSTON, March 11, 2025--Ayrmid Pharma Ltd., a cell therapy pioneer working to turn cells into powerful therapeutics and RoslinCT, a world leading cell and gene therapy contract …See details»
Company Overview - Gamida Cell
Cell Press Reviews, Trends in Immunology, April 2019, Vol. 40, No. 4 *Gamida Cell’s lead development candidate consists of omidubicel (expanded hematopoietic stem cells) and …See details»
1st FDA Approval Omisirge Expanded Cord Blood
On 17 April 2023, the FDA gave approval to the Gamida Cell product “Omisirge” (formerly known as Omidubicel, and before that as NiCord) 1,2.This is the first FDA market approval of an …See details»
OMISIRGE® (omidubicel-onlv) | Allogeneic Hematopoietic …
Gamida Cell Ltd.; 2023. Indication and Usage. Important Safety Information. Omisirge is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy derived from cord …See details»
Gamida inks restructuring deal to support off-the-shelf cell therapy
Apr 2, 2024 The news was long awaited for developer Gamida Cell, which twice underwent cost-cutting measures (in January 2022 and March 2023) as the FDA twice delayed the approval …See details»
Our R&D - Gamida Cell
Gamida Cell’s proprietary nicotinamide (NAM) technology expands the number of cells while maintaining their intrinsic properties, and enhances cellular functionality and phenotype. Our …See details»